Lafutidine-based triple therapy for Helicobacter pylori eradication.
For treating Helicobacter pylori infection, it is still debatable whether proton pump inhibitor can be replaced by H2-receptor antagonist without compromising efficacy. Lafutidine is a newly synthesized H2-receptor antagonist and has been shown to exhibit antisecretory action. This meta-analysis investigated the efficacy of lafutidine-based triple therapy for Helicobacter pylori infection. METHODOGY: We searched PUBMED; EMBASE, the Cochrane Library and Chinese Biomedical Database databases to identify randomized controlled trials regarding lafutidine-based triple therapy of Helicobacter pylori eradication. Thirteen potential studies were retrieved, of which 3 met our inclusion criteria. Overall we observed Helicobacter pylori eradication rates were similar in the lafutidine group and the lansoprazole group (OR, 1.03; 95% CI, 0.64-1.66). The OR for the active stage ulcer cure rate was 0.78 (95% CI, 0.35, 1.71) for lafutidine-based triple therapy compared with lansoprazole-based triple therapy. Likewise, we observed symptom response and adverse events were similar in both groups. Lafutidine-based triple therapy was as safe and effective as triple therapy including lansoprazole for Helicobacter pylori infection, and could be considered as an additional treatment option. However, more rigorous research is required to accurately assess the role of lafutidine in eradicating Helicobacter pylori infection.